XML 21 R5.htm IDEA: XBRL DOCUMENT v2.3.0.15
STATEMENTS OF CASH FLOWS (USD $)
6 Months Ended
Aug. 31, 2011
Aug. 31, 2010
CASH FLOWS FROM OPERATING ACTIVITIES  
Net loss$ (3,285,922)$ (2,579,873)
Adjustments to reconcile net loss to net cash used by operating activities:  
Depreciation354372
FDA clinical trial expenses paid directly by S.R. Burzynski, M.D., Ph.D.3,049,9652,295,872
Changes in operating assets and liabilities  
Accounts payable(36,006)54,781
Accrued liabilities(296)584
NET CASH USED BY OPERATING ACTIVITIES(271,905)(228,264)
CASH FLOWS FROM FINANCING ACTIVITIES  
Contribution of capital276,904226,598
NET CASH PROVIDED BY FINANCING ACTIVITIES276,904226,598
NET INCREASE (DECREASE) IN CASH4,999(1,666)
CASH AT BEGINNING OF PERIOD17,47618,122
CASH AT END OF PERIOD$ 22,475$ 16,456